Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Friday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Barclays decreased their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th.

Cellectis Stock Performance

Shares of Cellectis stock opened at $2.10 on Friday. The firm has a market cap of $116.72 million, a P/E ratio of -1.64 and a beta of 3.10. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a 12 month low of $1.70 and a 12 month high of $3.77. The stock’s fifty day moving average price is $1.95 and its 200-day moving average price is $2.18.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $18.05 million during the quarter, compared to analysts’ expectations of $5.00 million. During the same quarter last year, the firm earned ($0.31) EPS. On average, equities research analysts expect that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Cellectis

Several large investors have recently made changes to their positions in the company. XTX Topco Ltd purchased a new stake in Cellectis in the 2nd quarter valued at $29,000. First Affirmative Financial Network purchased a new stake in Cellectis in the 3rd quarter valued at $45,000. Principal Financial Group Inc. grew its holdings in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares in the last quarter. Finally, Long Focus Capital Management LLC grew its holdings in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares in the last quarter. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.